Are we closer to having drugs to treat muscle wasting disease?

Journal of Cachexia, Sarcopenia and Muscle

Volumn 5, Issue 2, 2014, Pages 83-87

  Morley, John E ^a   von Haehling, Stephan ^b   Anker, Stefan D ^b,c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR; BIMAGRUMAB; CYTOKINE RECEPTOR ANTAGONIST; ESPINDOLOL; GHRELIN; IMMUNOMODULATING AGENT; MEGESTROL ACETATE; OHR 118; PROTEIN INHIBITOR; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE; TROPONIN; UNCLASSIFIED DRUG;

CACHEXIA; EDITORIAL; HUMAN; MUSCLE ATROPHY; MUSCLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SARCOPENIA; SKELETAL MUSCLE; TREATMENT OUTCOME;

EID: 84902548421     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-014-0149-7     Document Type: Editorial

References (73)

1. Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. 2013;4: 173-8.
2. von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle. 2012;3: 213-7.
3. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14: 392-7.
4. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: european consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39: 412-23.
5. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011;12: 403-9.
6. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12: 249-56.
7. Lee WJ, Liu LK, Peng LN, Lin MH, Chen LK, ILAS Research Group. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: Results from the I-Lan longitudinal aging study. J Am Med Dir Assoc. 2013;14: 528. e1-7.
8. Malmstrom TK, Miller DK, Herning MM, Morley JE. Low appendicular skeletal muscle mass (ASM) with limited mobility and poor health outcomes in middle-aged African Americans. J Cachexia Sarcopenia Muscle. 2013;4: 179-86.
9. Landi F, Liperoti R, Fusco D, Mastropaolo S, Quattrociocchi D, Proia A, et al. Sarcopenia and mortality among older nursing home residents. J Am Med Dir Assoc. 2012;13: 121-6.
10. Morley JE. Weight loss in older persons: new therapeutic approaches. Curr Pharm Des. 2007;13: 3637-47.
11. Argiles JM, Anker SD, Evans WJ, Morley JE, Fearon KC, Strasser F, et al. Consensus on cachexia definitions. J Am Med Dir Assoc. 2010;11: 229-30.
12. Morley JE, Anker SD, Evans WJ. Cachexia and aging: an update based on the Fourth International Cachexia meeting. J Nutr Health Aging. 2009;13: 47-55.
13. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27: 793-9.
14. Argiles JM, Busquets S, Lopez-Soriano FJ, Costelli P, Penna F. Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle. 2012;3: 73-6.
15. Cadone Cadore EL, Izquierdo M. New strategies for the concurrent strength-, power-, and endurance-training prescription in elderly individuals. J Am Med Dir Assoc. 2013;14: 623-4.
16. Singh NA, Quine S, Clemson LM, Williams EJ, Williamson DA, Stavrinos TM, et al. Effects of high-intensity progressive resistance training and targeted multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: a randomized controlled trial. J Am Med Dir Assoc. 2012;13: 24-30.
17. Cavalheri V, Tahirah F, Nonoyama M, Jenkins S, Hill K. Exercise training for people following lung resection for non-small cell lung cancer - a Cochrane systematic review. Cancer Treat Rev 2013.
18. Gould DW, Lahart I, Carmichael AR, Koutedakis Y, Metsios GS. Cancer cachexia prevention via physical exercise: molecular mechanisms. J Cachexia Sarcopenia Muscle. 2013;4: 111-24.
19. Fragala MS, Jajtner AR, Beyer KS, Townsend JR, Emerson NS, Scanlon TC, et al. Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults. J Cachexia Sarcopenia Muscle 2013, in press. doi: 10. 1007/s13539-013-0120-z.
20. Boppart MD, De Lisio M, Zou K, Huntsman HD. Defining role for non-satellite stem cells in the regulation of muscle repair following exercise. Front Physiol. 2013;4: 310.
21. Tieland M, van de Rest O, Dirks ML, van der Zwaluw N, Mensink M, van Loon LJ, et al. Protein supplementation improves physical performance in frail elderly people: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2012;13: 720-6.
22. Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc. 2013;14: 542-59.
23. Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2009 (2): CD003288.
24. van Wetering C, Hoogendoorn M, Broekhuizen R, Geraerts-Keeris GJ, de Munck DR, Rutten-van Mölken MP, et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc. 2010;11: 179-87.
25. Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle. 2010;1: 35-42.
26. Neelemaat F, Bosmans JE, Thijs A, Seidell JC, van Bokhorst-de van der Schuren MA. Post-discharge nutritional support in malnourished elderly individuals improves functional limitations. J Am Med Dir Assoc. 2011;12: 295-301.
27. Gaskin FS, Farr SA, Banks WA, Kumar VB, Morley JE. Ghrelin-induced feeding is dependent on nitric oxide. Peptides. 2008;24: 913-8.
28. Argiles JM, Stemmler B. The potential of ghrelin in the treatment of cancer cachexia. Expert Opin Biol Ther. 2013;13: 67-76.
29. Miyazaki T, Tanaka N, Hirai H, Yokobori T, Sano A, Sakai M, et al. Ghrelin level and body weight loss after esophagectomy for esophageal cancer. J Surg Res. 2012;176: 74-8.
30. White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009;94: 1198-206.
31. Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fractures: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53: 183-9.
32. Temel J, Bondarde S, Jain M, Yun Y, Duus E, Allen S, et al. Efficacy and safety results from a phase II study of anamorelin HC21, a ghrelin receptor agonist, in NSCLC patients. J Cachexia Sarcopenia Muscle. 2013;4: 334. doi: 10. 1007/s13539-013-0123-9. Abstract 5-01.
33. Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J Am Med Dir Assoc. 2011;12: 62-7.
34. Chasen M, Bhargava R, Hirschmann S, Taraporewala I. Phase II study of OHR/AVR 118 in anorexia-cachexia. J Cachexia Sarcopenia Muscle. 2013;4: 335. doi: 10. 1007/s13539-013-0123-9. Abstract 5-04.
35. Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;3, CD004310.
36. Karcic E, Philpot C, Morley JE. Treating malnutrition with megestrol acetate: literature review and review of our experience. J Nutr Health Aging. 2002;6: 191-200.
37. Wen HS, Li X, Cao YZ, Zhang CC, Yang F, Shi YM, et al. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy. 2012;58: 461-7.
38. Cuvelier GD, Baker TJ, Peddi EF, Casey LM, Lambert PJ, Distefano DS, et al. A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy. Pediatr Blood Cancer 2013, in press. doi: 10. 1002/pbc. 24828.
39. Yeh SS, Schuster MW. Megestrol acetate in cachexia and anorexia. Int J Nanomedicine. 2006;1: 411-6.
40. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20: 567-73.
41. Schoedel KA, Harrison SJ. Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research. Curr Pharm Des. 2012;18: 5008-14.
42. Morley JE. End-of-life care in the nursing home. J Am Med Dir Assoc. 2011;12: 77-83.
43. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ. et al; European Association of Urology; European Academy of Andrology; American Society of Andrology. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009;55: 121-30.
44. Morley JE. Androgens and aging. Maturitas. 2001;38: 61-71.
45. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95: 639-50.
46. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90: 1502-10.
47. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58: 1134-43.
48. Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66: 1090-9.
49. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54: 919-27.
50. Iellamo F, Volterrano M, Caminiti G, Karam R, Massaro R, Fini M, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 2010;56: 1310-6.
51. Chapman IM, Visvanathan R, Hammond AJ, Morley JE, Field JB, Tai K, et al. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr. 2009;89: 880-9.
52. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2: 153-61.
53. Dobs AS, Boccia RV, Croot CC, Gabrial NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomized controlled phase 2 trial. Lancet Oncol. 2013;14: 335-45.
54. Steiner MS. Enobasarm, a selective androgen receptor modulator, increases lean body mass in advanced non-small cell lung cancer patients in two pivotal, international phase 3 trials. J Cachexia Sarcopenia Muscle. 2013;4: 68. doi: 10. 1007/s13539-013-0123-9. Abstract 5-15.
55. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011;2: 143-51.
56. Morley JE. Developing novel therapeutic approaches to frailty. Curr Pharm Des. 2009;15: 3384-95.
57. Tisdale MJ. Reversing cachexia. Cell. 2010;142: 511-2.
58. Attie KM, Brogstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47: 416-23.
59. Machado P, Brady S, Hanna MG. Update in inclusion body myositis. Curr Opin Rheumatol. 2013;25: 763-71.
60. Rooks D. Targeting myostatin and activin receptors. Abstracts, 7th Cachexia Conference. Kobe, 2013, p. 49.
61. Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ. 2007;177: 867-74.
62. Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo ME. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomized double blind placebo controlled trial. Heart. 2002;88: 373-7.
63. Peters R, Beckett N, Burch L, de Vernejoul MC, Liu L, Duggan J, et al. The effect of treatment based on diuretic (indapamide) +/- ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). Age Ageing. 2010;39: 609-16.
64. Steward Coats AJ, Srinivasan Surendran J, Chicarmana H, Vangipuram SR, Bhatt NN, Jain M, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. 2011;2: 201-7.
65. Coats AJS. Novel beta blockers. Abstracts, 7th Cachexia Conference. Kobe 2013, p. 51.
66. Malik F. Fast skeletal muscle troponin activators and their application to disease-preclinical characterization. Abstracts, 7th Cachexia Conference. Kobe, 2013, p. 50.
67. Gomes AP, Price N, Ling AJY, Moslehi JJ, Montgomery MK, Rajman L, et al. Declining NAD + induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155: 1624-38.
68. Chen YF, Wu CY, Kirby R, Kao CH, Tsai TF. A role for the CISD2 gene in lifespan control and human disease. Ann NY Acad Sci. 2010;1201: 58-64.
69. Chen YF. The mitochondrial contribution to muscle atrophy in aging and disease. Abstracts, 7th Cachexia Conference. Kobe, 2013, p. 37.
70. Sabbah MN. Long-term therapy with Bendavia (MTP-131), a novel mitochondria-targeting peptide, normalizes skeletal muscle fiber type composition in dogs with chronic heart failure. Abstracts, 7th Cachexia Conference. Kobe, 2013, p. 54.
71. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1: 129-33.
72. Fearon K, Evans WJ, Anker SD. Myopenia-a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle. 2011;2: 1-3. 73.
73. Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, et al. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle. 2014;5: 1-3.